The CAR T-cell field in MM has made several strides since the first BCMA-targeted CAR was developed nearly 10 years ago. Results from the pivotal phase 2 KarMMa study of idecabtagene vicleucel (ide-cel) shows promise with rapid, deep, and durable responses in patients with triple-class-exposed relapsed and refractory myeloma.
The ORR at primary analysis was 72% at a median follow-up of 13.2 months. Furthermore, 55% of patients experienced a very good partial response (VGPR) or better, with 93% of evaluable patients being MRD negative.
Ide-cel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It is indicated in adult patients with R/R multiple myeloma following 4+ prior lines of therapy. These prior lines of therapy include an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Ide-cel was approved by the FDA in March 2021, and each dose is a customized treatment developed based on the patient’s own T-cells. These T-cells are collected and genetically modified to incorporate a new gene that targets and kills myeloma cells. Modified cells are infused into the patient.
What have your experiences with ide-cel been compared with other BRMA-targeted CAR T cell therapy? In your opinion/experience, will ide-cel have a prominent place in R/R multiple myeloma?
Show More Comments
-
Albert Dekker January 14, 2023
I think with BITEs there will be more room for CAR-T patients at academic centers -
Ali Mirmiran January 14, 2023
I have had personal experience using ABECMA in my patients. I had seen good responses and reasonably good tolerability in my patients.
